General Annual Meeting (GAM)
This folder contains all the recordings of the GAM.
Closure
39th General Annual Meeting of the Belgian Hematology Society - Day 2 - Closure
AMGINY, BeiGeneration, Gilead, PACE & SAFYHR Awards
39th General Annual Meeting of the Belgian Hematology Society - Day 2 - Session VI : AMGINY, BeiGeneration, Gilead, PACE & SAFYHR Awards
Satellite 3: GSK | Infection prevention and management in the era of novel agents
39th General Annual Meeting of the Belgian Hematology Society - Day 2 - Satellite 3 : GSK | Infection prevention and management in the era of novel agents
Highlight 2 | How I treat in 2024: Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia
39th General Annual Meeting of the Belgian Hematology Society - Day 2 - Session V : Highlight 2 | How I treat in 2024: Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia
Satellite 2 – AstraZeneca | Navigating the increasing complexity of Chronic Lymphocytic Leukemia treatments: a practical approach
39th General Annual Meeting of the Belgian Hematology Society - Day 2 - Satellite 2 : AstraZeneca | Navigating the increasing complexity of Chronic Lymphocytic Leukemia treatments: a practical approach
Best Oral and Poster Awards
39th General Annual Meeting of the Belgian Hematology Society - Day 1 - Best Oral and Poster Awards
Ethics & Economy
39th General Annual Meeting of the Belgian Hematology Society - Day 1 - Session IV : Ethics & Economy
Pierre Stryckmans Lecture
39th General Annual Meeting of the Belgian Hematology Society - Day 1 - Session III : Pierre Stryckmans Lecture
Special Lecture 2
39th General Annual Meeting of the Belgian Hematology Society - Day 1 - Special Lecture 2
Oral Abstracts
39th General Annual Meeting of the Belgian Hematology Society - Day 1 - Oral Abstracts
Special Lecture 1
39th General Annual Meeting of the Belgian Hematology Society - Day 1 - Special Lecture 1
Satellite 1 - Sanofi | State-of-the-art NK cells therapies in hematological malignancies
39th General Annual Meeting of the Belgian Hematology Society - Day 1 - Satellite 1 : Sanofi | State-of-the-art NK cells therapies in hematological malignancies